LarissaA.KordeMDMPH

Oncology • Seattle, WA

Breast Cancer, Hematologic Oncology

Associate professor

Join to view full profile

Dr. Korde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Korde's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Medical Oncology, 2002 - 2004
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1998 - 2001
New York Medical CollegeClass of 1998

Certifications & Licensure

DC State Medical License 2001 - 2024
MD State Medical License 2019 - 2024
WA State Medical License 2009 - 2020
VA State Medical License 1998 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Start of enrollment: 2005 Nov 28
Completed
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Recruiting
Phase 2
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Start of enrollment: 2010 Sep 01
Active, not recruiting
Phase 2
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 2
NCI COVID-19 in Cancer Patients, NCCAPS Study Start of enrollment: 2020 Jun 05
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

1 citations
The New NCI Precision Medicine Trials.
Lyndsay N Harris, Charles D Blanke, Harry P Erba, James M Ford, Robert J Gray, Michael L LeBlanc, Siwen Hu-Lieskovan, Mark R Litzow, Selina M Luger, Funda Meric-Bernst...> ;Clinical Cancer Research. 2023 Dec 1
Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease.
Boris Freidlin, Larissa A Korde, Edward L Korn> ;Journal of Clinical Oncology. 2023 Oct 10
4 citations
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
Jennifer K Litton, Meredith M Regan, Lajos Pusztai, Hope S Rugo, Sara M Tolaney, Elizabeth Garrett-Mayer, Laleh Amiri-Kordestani, Reva K Basho, Ana F Best, Jean-Franco...> ;Journal of Clinical Oncology. 2023 Sep 20
8 citations
Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx...
Olga Kantor, Tari A King, Rachel A Freedman, Erica L Mayer, Mariana Chavez-MacGregor, Larissa A Korde, Joseph A Sparano, Elizabeth A Mittendorf> ;JAMA Surgery. 2023 Jun 1
Response to Song.
Larissa A Korde, Ana F Best> ;Journal of the National Cancer Institute. 2023 Jun 8
117 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost, John R Hyngstrom, Siwen Hu-Lieskovan, Christopher D Lao, Leslie A Fecher, Thach-Giao Truon...> ;The New England Journal of Medicine. 2023 Mar 2
2 citations
COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).
Ana F Best, Melissa Bowman, Jessica Li, Grace E Mishkin, Andrea Denicoff, Marwa Shekfeh, Larry Rubinstein, Jeremy L Warner, Brian Rini, Larissa A Korde> ;Journal of the National Cancer Institute. 2023 May 8
ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx.
Olga Kantor, Harold J Burstein, Tari A King, Steven Shak, Christy A Russell, Armando E Giuliano, Gabriel N Hortobagyi, Eric P Winer, Larissa A Korde, Joseph A Sparano,...> ;Annals of Surgical Oncology. 2022 Dec 1
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Olga Kantor, Harold J Burstein, Tari A King, Steven Shak, Christy A Russell, Armando E Giuliano, Gabriel N Hortobagyi, Eric P Winer, Larissa A Korde, Joseph A Sparano,...> ;Annals of Surgical Oncology. 2022 Dec 1
1 citations
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTT...
Guilherme Nader-Marta, Véronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Sa...> ;British Journal of Cancer. 2022 Nov 1
1 citations
Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
Praveen Vikas, Larissa A Korde, Mark R Somerfield, Dawn L Hershman> ;JCO Oncology Practice. 2022 Sep 1
11 citations
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Larissa A Korde, Mark R Somerfield, Dawn L Hershman> ;Journal of Clinical Oncology. 2022 May 20
17 citations
Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.
Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khusha...> ;Cancer Discovery. 2021 Nov 11
33 citations
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade ...
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J Haley, Anna Maria Storniolo, Mridula P ...> ;Clinical Cancer Research. 2021 Oct 29
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N06...
Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, Larissa A Korde, Florentine Hilbers, Christian Jackisch, Olena Werner, Richard D Gelber, Aminah Jatoi, Amylou C D...> ;Breast Cancer Research and Treatment. 2022 Jan 1
23 citations
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith R....> ;Breast. 2021 Oct 1
88 citations
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, Ali Dorris, Lesley Fallowfield, Dharamvir Jain, Stephen R. D. Johnston, Larissa A. Korde, Jennifer K. Litton, ...> ;Journal of Clinical Oncology. 2021 Jul 29
4 citations
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
Jane Bayani, C. Poncet, Cheryl Crozier, Anouk Neven, Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith...> ;NPJ Breast Cancer. 2021 Jul 26
568 citations
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt, Judy Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susa...> ;The New England Journal of Medicine. 2021 Jun 3
2 citations
A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape.
Courtney D. DiNardo, Larissa A. Korde, Matthew B. Yurgelun> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2021 May 19
43 citations
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M. Tolaney, Elizabeth Garrett-Mayer, Julia White, Victoria S. Blinder, Jared C. Foster, Laleh Amiri-Kordestani, E. Shelley Hwang, Judith M Bliss, Eileen Rakovitch...> ;Journal of Clinical Oncology. 2021 May 18
10 citations
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
Alvaro Moreno-Aspitia, Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances M. Boyle, David W. Hillman, Larissa A. Korde, Debora Fumagalli, Miguel Izquierdo...> ;European Journal of Cancer. 2021 May 1
11 citations
A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer
, , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Feb 15
299 citations
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A. Korde, Mark R. Somerfield, Lisa A. Carey, Jennie R. Crews, Neelima Denduluri, E. Shelley Hwang, Seema A. Khan, Sibylle Loibl, Elizabeth A. Morris, Alejandra...> ;Journal of Clinical Oncology. 2021 Jan 28
10 citations
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, Noam Pondé, Andrea Gombos, Vicki Paterson, Florentine Hilbers, Larissa A. Korde, Anna Manukyants, Amylou C. Due...> ;Journal of the National Comprehensive Cancer Network. 2021 Jan 5
Join now to see all

Journal Articles

Prognostic Gene Expression Profiling in Cutaneous Melanoma
Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology

Abstracts/Posters

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adult...
Larissa Korde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Authored Content

Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020

Press Mentions

Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaFebruary 24th, 2023
A Safer, Better Treatment Option for Some Younger Women With Breast CancerJanuary 11th, 2023
Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaSeptember 11th, 2022
Join now to see all